(Q26784569)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Transmission and spreading of tauopathy in transgenic mouse brain

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A protein factor essential for microtubule assembly

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Neuropathological stageing of Alzheimer-related changes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Neuroinflammation in Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Control of peripheral nerve myelination by the beta-secretase BACE1

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Regulation of NMDA receptor trafficking by amyloid-beta

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A specific amyloid-beta protein assembly in the brain impairs memory

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Alzheimer's disease: the amyloid cascade hypothesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

What does it mean to be 'amyloid-positive'?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Invited review: Prion-like transmission and spreading of tau pathology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Oligomer formation of tau protein hyperphosphorylated in cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A data-driven model of biomarker changes in sporadic Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Ectosomes: a new mechanism for non-exosomal secretion of tau protein

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Biomarker modeling of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Neuroimaging and the search for a cure for Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

The future of blood-based biomarkers for Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Fluid biomarkers in Alzheimer's disease - current concepts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

CSF biomarker variability in the Alzheimer's Association quality control program

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Brain amyloid-β oligomers in ageing and Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Plasma tau levels in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Advances in designs for Alzheimer's disease clinical trials.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Use of proteomic methods in the analysis of human body fluids in Alzheimer research

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Neurotoxicity of amyloid β-protein: synaptic and network dysfunction

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

The mechanism of γ-Secretase dysfunction in familial Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Salivary tau species are potential biomarkers of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Incidence of post-dural puncture headache in research volunteers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Amyloid beta and APP as biomarkers for Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Developing novel immunogens for a safe and effective Alzheimer's disease vaccine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Longitudinal study of CSF biomarkers in patients with Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Impact of amyloid imaging on drug development in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Tau alteration and neuronal degeneration in tauopathies: mechanisms and models

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Hyperphosphorylation-induced tau oligomers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Amyloid-β forms fibrils by nucleated conformational conversion of oligomers

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

31 May 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

How can we recognize "disease modification" effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Biomarkers in Alzheimer's disease drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Age, neuropathology, and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Bace1 modulates myelination in the central and peripheral nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Determination of serum visinin like protein-1 and its potential for the diagnosis of brain injury due to the stroke: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Tau proteins in serum predict outcome after severe traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Plasma Complement factor H in Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Blood-based protein biomarkers for diagnosis of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Developing a simple laboratory test for Alzheimer's disease: measuring acetylcholinesterase in saliva - a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Gene mutation defends against Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00186

Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

In VivoAssessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

Mutational and biophysical studies suggest RC3/neurogranin regulates calmodulin availability

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553391

28 November 2018

1 reference

12 December 2020

Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse

1 reference

12 December 2020

2013 Alzheimer's disease facts and figures

1 reference

12 December 2020

Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury

1 reference

12 December 2020

Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk

1 reference

12 December 2020

Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease

1 reference

12 December 2020

Expression of the neuronal calcium sensor protein family in the rat brain

1 reference

12 December 2020

Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men

1 reference

12 December 2020

Identifiers

DOI

10.3389/FNEUR.2015.00186

1 reference

1 reference

1 reference

PubMed publication ID

26379620

1 reference